Department of Radiation Oncology, University of North Carolina School of Medicine, 101 Manning Drive CB #7512, Chapel Hill, NC, 27514, USA.
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Radiat Oncol. 2023 Jun 2;18(1):94. doi: 10.1186/s13014-023-02289-2.
Para-aortic lymph node (PALN) metastases from primary pelvic malignancies are often treated with resection, but recurrence is common. We report toxicity and oncologic outcomes for patients with PALN metastases from gastrointestinal and gynecologic malignancies treated with resection and intraoperative electron radiotherapy (IORT).
We retrospectively identified patients with recurrent PALN metastases who underwent resection with IORT. All patients were included in the local recurrence (LR) and toxicity analyses. Only patients with primary colorectal tumors were included in the survival analysis.
There were 26 patients with a median follow up of 10.4 months. The rate of para-aortic local control (LC) was 77% (20/26 patients) and the rate of any cancer recurrence was 58% (15/26 patients). Median time from surgery and IORT to any recurrence was 7 months. The LR rate for those with positive/close margins was 58% (7/12 patients) versus 7% (1/14 patients) for those with negative margins (p = 0.009). 15% (4/26 patients) developed surgical wound and/or infectious complications, 8% (2/26 patients) developed lower extremity edema, 8% (2/26 patients) experienced diarrhea, and 19% (5/26 patients) developed an acute kidney injury. There were no reported nerve injuries, bowel perforations, or bowel obstructions. For patients with primary colorectal tumors (n = 19), the median survival (OS) was 23 months.
We report favorable LC and acceptable toxicity for patients receiving surgical resection and IORT for a population that has historically poor outcomes. Our data show disease control rates similar to literature comparisons for patients with strong risk factors for LR, such as positive/close margins.
原发于盆腔的恶性肿瘤的腹主动脉旁淋巴结(PALN)转移通常通过切除术治疗,但复发很常见。我们报告了接受切除术和术中电子放射治疗(IORT)治疗胃肠道和妇科恶性肿瘤 PALN 转移患者的毒性和肿瘤学结果。
我们回顾性地确定了接受 IORT 联合切除术治疗的复发性 PALN 转移患者。所有患者均纳入局部复发(LR)和毒性分析。仅包括原发性结直肠肿瘤患者进行生存分析。
共有 26 例患者,中位随访时间为 10.4 个月。腹主动脉旁局部控制率(LC)为 77%(26 例中有 20 例),任何癌症复发率为 58%(26 例中有 15 例)。从手术和 IORT 到任何复发的中位时间为 7 个月。阳性/接近切缘的 LR 率为 58%(12 例中有 7 例),阴性切缘的 LR 率为 7%(14 例中有 1 例)(p=0.009)。15%(26 例中有 4 例)发生手术切口和/或感染性并发症,8%(26 例中有 2 例)发生下肢水肿,8%(26 例中有 2 例)发生腹泻,19%(26 例中有 5 例)发生急性肾损伤。没有报告神经损伤、肠穿孔或肠梗阻。对于原发性结直肠肿瘤患者(n=19),中位生存(OS)为 23 个月。
我们报告了接受手术切除和 IORT 治疗的患者具有良好的 LC 和可接受的毒性,这些患者的历史结局较差。我们的数据显示,对于 LR 风险因素较强的患者(如阳性/接近切缘),疾病控制率与文献比较相似。